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Abstract
Objective: To assess patterns of anti-osteoporosis medication (AOM) use over 3 years among women at high risk of major
fracture.
Methods: The GLOW registry follows a cohort of more than 40,000 women aged $55 from 615 primary care practices in 10
countries. Self-administered surveys (baseline, 12, 24, and 36 months) collected data on patient characteristics, perception
of fracture risk, and AOM use. FRAX scores were calculated from the baseline surveys and women classified as high risk if
their FRAX 10-year probability of major fracture was $20%.
Results: A total of 5774 women were classified as at high risk and had complete data over 3 years. At baseline, 2271 (39%)
reported receiving AOM, 739 (13%) reported prior but not current use, and 2764 (48%) said they had never used AOM. Over
3 years, 85% of baseline non-users continued as non-users and 15% initiated AOM; among baseline users, 49% continued
the same medication class, 29% stopped AOM, and 12% switched. Women who stopped AOM were less likely to self-report
osteoporosis (HR 0.56, 95% CI 0.42–0.75) than women who continued AOM. Compared with non-users who did not begin
treatment, women initiating AOM were more likely to report a diagnosis of osteoporosis (HR 11.3, 95% CI 8.2–15.5) or
osteopenia (HR 4.1, 95% CI 2.9–5.7) and be very concerned about osteoporosis (HR 1.9, 95% CI 1.3–2.8).
Conclusions: Less than 40% of women at high risk of fracture reported taking AOM. Women who stopped AOM were less
likely to believe they have osteoporosis. Women who initiated treatment appeared motivated primarily by a diagnosis of
osteoporosis or osteopenia and concern about the condition.
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Introduction
Anti-osteoporosis medications (AOMs) are efficacious in reduc-
ing risk of fractures in postmenopausal women [1–3]. Unfortu-
nately, effective fracture prevention has been hampered by sub-
optimal prescribing of medications to high-risk women [4–6] and
low adherence among women who have started AOM [7–9].
Identifying factors associated with patterns of use of these
medications has the potential to improve prescribing and
adherence. Data from the large international Global Longitudinal
Study of Osteoporosis in Women (GLOW) provide an opportunity
to explore these associations.
We selected postmenopausal women at high risk of major
fracture, as determined by the World Health Organization FRAX
tool [10,11], to describe patterns of AOM use during 3 years of
observation and to identify characteristics associated with these
patterns.
Methods
Ethics Statement
Each study site obtained ethics committee approval to conduct
the study in the specific location.
Study Design
GLOW is an observational cohort study conducted in physician
practices in 17 sites in 10 countries (Australia, Belgium, Canada,
France, Germany, Italy, Netherlands, Spain, UK, and USA).
Details of the study design and methods have been described
previously [12]. In brief, study sites were selected based on
geographic distribution and the presence of lead investigators with
expertise in osteoporosis and access to a research team capable of
managing a large cohort of subjects. Investigators identified
primary care practices in their region that were able to supply
names and addresses of their patients electronically. The
composition of groups varied by region and included health-
system owned and independent practices and health maintenance
organizations. Each practice provided a list of the names and
addresses of women aged $55 years who had been attended by
their physician in the past 24 months. All eligible women aged
$65 years and a random sample of 50% of women ,65 years of
age were recruited from each practice. Patients who were unable
to complete the study survey due to cognitive impairment,
language barriers, institutionalization, or illness were not included.
Questionnaires were designed to be self-administered and
covered domains including: patient characteristics and risk factors;
perception of fracture risk and osteoporosis; medication use
(current or ever taken); selected medical diagnoses; healthcare
access and use; physical activity; and physical and emotional
health status. Where possible, items from validated instruments
were used, including the National Health and Nutrition Exam-
ination Survey (NHANES) [13], EuroQol (EQ-5D) [14,15], and
the Physical Function Component of the SF-36 [16–18].
All information was self-reported. For the baseline survey,
subjects were asked to identify fractures they had experienced
since the age of 45 years for any of 10 specified locations: clavicle,
upper arm, wrist, spine, rib, hip, pelvis, upper leg, lower leg, and
ankle. When more than one fracture was reported, each was
counted to obtain the total fractures by site. Women’s self-reports
of prior fracture were not validated from independent records.
FRAX scores were calculated for all women from responses on
their baseline surveys. Women missing variables required to
calculate a FRAX score were excluded from further analysis.
Women were classified as ‘‘high risk’’ if their FRAX 10-year
probability of major fracture was $20%.
AOMs were grouped as: oral bisphosphonates (alendronate,
etidronate, ibandronate, risedronate); bisphosphonate infusion
(pamidronate, zolendronic acid); and parathyroid hormone. All
other classes of AOM included only one medication and were
analyzed separately, and included calcitonin, raloxifene, strontium
ranelate, and tibolone. Estrogen-containing medications that may
have been prescribed as hormone-replacement therapy were not
included.
AOM usage categories were formed for women who reported
one class of AOM in each survey year (baseline, year 1, year 2, and
year 3). Women who reported current AOM use at baseline were
considered as having ‘‘Stopped AOM’’ at the first survey with no
current use reported. Women who reported current AOM use at
baseline and a different class in a subsequent survey were
considered as having ‘‘Switched AOM’’ in the year of change.
Women who both stopped and switched were counted only as
having switched. Women who reported no current use of AOM at
baseline but current use in a later year were designated as
‘‘Initiated AOM’’ in the first year of current use. Women who
reported current use of the same class of AOM in each survey year
were designated as ‘‘Continuous use, same class,’’ and women who
reported no past use of AOM at baseline and no current use
during any survey year were designated as ‘‘Never used AOM.’’
Women missing any survey or with incomplete AOM or outcome
data were excluded from the analysis.
Separate models were fit for the outcomes of stopping, starting,
and switching AOM use using multiple Cox regression. Risk
factors whose status could change over survey years were modeled
as time-varying covariates (TVCs). Because the relative timing of
TVC and outcome was not known if they co-occurred in the same
survey year, model log likelihoods were compared for models
where TVC status in year t was determined solely by its status in
year t (same survey year as outcome); solely by its status in year t–1
(prior survey); and by its status in year t–1 and year t (year t status
yes, if yes in prior or same year as outcome). In most instances it is
reasonable to suppose the TVC precedes the outcome if they co-
occur; however, if the improvement in model likelihood under a
different timing assumption had a p-value #0.05 (chi-square test),
the improved model was reported.
All three models were fit separately using backwards stepwise
selection, beginning with all variables identified as significant
(p,0.20) in the univariate analyses. These are shown in Table S1.
Country was also included in each model as a fixed effect.
Variables that remained significant (p#0.05) were retained in the
final model. The c index for each model was computed using the
Harrell macro for Cox regression [19]. This macro was modified
to incorporate, where applicable, changing risk factor status over
the survey years. All analyses were conducted in SAS versions 9.2
and 9.3 (SAS Institute, Cary, NC).
Results
Among the .100,000 women mailed an invitation to partic-
ipate, the median participation rate across the 17 study sites was
62%. At study baseline, 40,228 women had recorded FRAX
scores; 8532 (21%) had a 10-year probability $20% of sustaining
a major fracture and were designated ‘‘high risk’’. Of the high-risk
women, 5774 (68%) had complete fracture and medication follow-
up data through survey year 3 and comprise the manuscript data
set. At baseline, 2764 (48%) women said they had never used
AOM; 2271 (39%) women reported current use of an AOM; and
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739 (13%) said they were not taking AOM now but had in the past
(Figure 1).
Over the ensuing 3 years, 2337 (85%) of baseline non-users
continued as non-users and 427 (15%) initiated use (Figure 1).
Among baseline users, 1103 (49%) continued use of the same class
of medication for the entire follow-up, 655 (29%) stopped and did
not restart use, 264 (12%) switched class of medication, and 249
(11%) reported intermittent use. Of the women reporting past but
not current use at baseline, 517 (70%) continued as non-users or
intermittent users and 222 (30%) re-started AOM.
Table 1 displays the baseline risk characteristics for the lower-
risk and high-risk women. High-risk women were on average older
and had lower weight and height. Frequencies of FRAX risk
factors were greater among high-risk women, with the exceptions
of cigarette smoking and increased alcohol use.
Table S1 summarizes results of univariate analyses of high-risk
women who altered their AOM use during the course of the study
by stopping AOMs, switching class of AOM, or starting
medication. Compared with those who used AOM continuously,
women who stopped their medication were less likely to be $75
years of age, to have received a diagnosis of osteoporosis, to report
fair or poor health, to be very concerned about osteoporosis, or
rate their fracture risk as higher than that of their peers.
Also compared with those who used AOM continuously,
women who switched their medication to a different class had
lower body mass indexes, were more likely to have fallen, and
reported more multiple fractures both at baseline and in the
preceding 12 months. HRs were .1 for most fracture sites, again
at baseline and in the preceding 12 months (Table S1). These
women had a higher self-reported rate of secondary osteoporosis, a
greater frequency of co-occurring conditions, and more often said
they had been diagnosed with osteoporosis. They were also more
likely to say that their health was fair or poor, expressed greater
Figure 1. Patient flow chart.
doi:10.1371/journal.pone.0082840.g001
Table 1. Baseline characteristics of the lower-risk and high-risk populations.
Lower-risk women
(n=22,002)
High-risk women
(n=5774)
Age, years 64 (60–70) 76 (71–81)
Weight, kg 68 (60–79) 63 (56–71)
Height, cm 163 (157–166) 160 (155–165)
Previous fracturea 2430 (11) 3614 (63)
Parental hip fracture 2783 (13) 2279 (39)
Current smoking 1668 (7.6) 394 (6.8)
Glucocorticoid use 339 (1.5) 407 (7.1)
Rheumatoid arthritis 126 (0.6) 112 (1.9)
Alcohol consumption .20 units per week 106 (0.5) 32 (0.6)
Secondary osteoporosisb 3686 (17) 1620 (28)
Data are median (interquartile range) or count (percentage).
aFracture since age 45 of clavicle or collar bone, upper arm, wrist, spine, rib, hip, pelvis, ankle, upper leg, or lower leg.
bType 1 diabetes; menopause before age 45 years; diagnosis of ulcerative colitis or celiac disease; or current use of anastrozole, letrozole, or exemestane.
doi:10.1371/journal.pone.0082840.t001
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concern about osteoporosis, and rated their perceived risk of
fracture as increased relative to that of their peers.
Compared with those who never used AOM, women who
initiated treatment had lower body mass indexes, were more likely
to report a fall in the preceding 12 months, and reported a greater
frequency of baseline and incident fractures (Table S1). They were
more often current glucocorticoid users and more often reported
diagnoses of osteoporosis and osteopenia. General health was
more likely to be rated fair or poor, physical function was
somewhat lower, and greater concern about osteoporosis and
fracture risk was noted.
Results of multivariable modeling to identify factors indepen-
dently associated with patterns of use are shown in Figures 2–4.
The only factor independently associated with an increased
likelihood of stopping medication was the absence of the diagnosis
of osteoporosis (Figure 2) (i.e. women reporting a diagnosis of
osteoporosis were less likely to discontinue AOM). The c-index of
0.58 for the model demonstrated little discrimination between
those who stopped and those who continued AOM [20].
Characteristics associated with switching AOM included
multiple incident fractures, decreasing body mass index, a
diagnosis compatible with secondary osteoporosis, and multiple
co-occurring conditions (Figure 3). Heightened concern about
osteoporosis and risk of fracture were also predictors for switching.
The c-index for the model was 0.70.
Most strongly associated with initiating AOM treatment was
having a diagnosis of osteoporosis or osteopenia (Figure 4).
Incident fractures in the past 12 months, increasing EQ-5D score,
and current use of glucocorticoids were associated with starting
treatment, as were increased levels of concern about osteoporosis
or risk of fracture (Figure 4). Reports of prior fractures at baseline
and history of parental hip fracture were negatively associated with
starting medication. The c-index for the model demonstrated
moderate discrimination (0.77).
Discussion
In this large, international cohort of high-risk postmenopausal
women, we looked for characteristics that could help explain
patterns of medication use. Among nearly 6000 women, only 39%
were taking an AOM at baseline and 48% had no current or past
exposure to the medications. Over the 3 years of observation, 49%
of baseline AOM users continued use of their baseline class of
AOM and 85% of non-users continued as non-users. Among the
baseline AOM users, 29% stopped their medication and 12%
switched class of medication. Nineteen percent of baseline non-
users initiated treatment.
Multivariable models identified several established risk factors,
including low body mass index, prior fractures, and use of
glucocorticoid that contributed to the identification of women who
initiated and who switched medications. Women who reported a
history of a previous fracture or that a parent had suffered a hip
fracture on the baseline survey were less likely to start AOM. This
apparent paradox may reflect a continuing decision of a subgroup
of women who have already considered these risk factors and
elected to forego AOM treatment. Only the absence of a diagnosis
of osteoporosis was significantly associated with stopping AOM,
and the low c-index (0.58) indicated that modeling was unable to
produce factors that identified women who were likely to be non-
persistent. FRAX variables were generally less robust predictors of
medication behavior than factors such as a diagnosis of
osteoporosis, concern about osteoporosis, and self-perceived
fracture risk. Two FRAX variables, cigarette smoking and heavy
alcohol use, showed similar frequencies among high risk and lower
risk women (Table 1) and also failed to predict medication use. It
appears that women with clinical risk factors may not recognize
the underlying fracture risk they are carrying and/or that
physicians may not actively screen women for fracture risk. The
findings also suggest that patterns of use may be driven less by
reactions to specific risk factors than by the labeling of the
condition and a woman’s sense of susceptibility to osteoporosis and
fracture. Indeed, some physicians may be reluctant to offer AOM
to women who do not meet bone mineral density criteria for a
diagnosis of osteoporosis given controversy over the efficacy of
treating patients with bone density results above this level [21–24].
Our observations are consistent with other research. There is
repeated evidence that most women with increased risk of fracture
go untreated [25–27]. In a previous report from GLOW,
Greenspan et al. [25] found that just 17% of treatment-naive
women with a new fracture had begun an AOM in the first year of
follow-up. Furthermore, Bessette et al. [26] found that only 26%
of women who sustained fragility fractures had been treated within
Figure 2. Multivariable HRs predicting stopping AOM (c=0.58). AOM, anti-osteoporosis medication; CI, confidence interval; HR, hazard ratio.
doi:10.1371/journal.pone.0082840.g002
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6–8 months of the event. Lastly, Ryder et al. [27] reported that
only 13% of older, community-dwelling women with low bone
density indications for anti-fracture therapy were taking anti-
resorptive medication.
In previous studies, the patient characteristics most strongly
associated with treatment initiation include low bone density and/
or the diagnosis of osteoporosis (both documented and self-
reported) [25–30]. In the current study, self-report of osteoporosis
was the strongest predictor for initiating treatment, but we did not
examine bone density. Older age, [26,29], low body mass index
[29], specific fracture sites (hip, spine, femur, pelvis) [25,26], and
use of calcium and/or vitamin D supplements [25,26], have also
predicted treatment in some studies. Similarly to the current study,
health beliefs such as susceptibility to osteoporosis and efficacy of
AOM treatment have been found by others [30,31].
Declining persistence in taking osteoporosis medications over
time has also been repeatedly demonstrated [7,9]. In a systematic
review that included 14 databases, Cramer et al. [7] found that
persistence with bisphosphonate treatment for osteoporosis at 1
year ranged from 18% to 78%. Kothawala et al. [9] reported that,
typically, only 50% of women prescribed an AOM are taking the
medicine 12 months later.
Factors that influence persistence with therapy are similar to
those related to initiation [7,8,32–34]. Women with a diagnosis of
osteoporosis or low bone mineral density [32–34] and those with a
previous fracture [8,33] are most likely to persist with treatment.
Younger women tend to be more persistent, [8] as are women with
belief in the efficacy of medication [34]. Silverman et al. [35]
noted that women who do not adhere to medications ‘‘may not
believe that they have osteoporosis or that they are not at much
risk of fracture,’’ an observation consistent with our findings.
Much research has utilized data from administrative databases
to explore the effect of dosing regimens (daily versus weekly) on
adherence [7,8]. These sources are limited to measuring variables
such as prescription refills and medication possession ratios and
cannot explore patient attitudes and concerns that may influence
adherence. We did not collect dosing information from our
subjects, but we were able to assess women’s concerns about
osteoporosis and perceived risks of fracture, which had a strong
influence on medication use.
Limitations and Strengths
Firstly, our data related to medication use are self-reported and
have not been confirmed by pharmacy records. However, a recent
report showed reasonable agreement when patient self-report of
use of osteoporosis drugs was compared with pharmacy data [36],
and a review by Garber et al. [37] found that self-reports of
medication adherence from questionnaires had moderate-to-high
concordance with electronic measures. Secondly, diagnoses of
osteoporosis and osteopenia were not verified. There is likely both
some over- and some under-reporting of both conditions. It is,
however, less the ‘‘accurate diagnosis of osteoporosis’’ than
‘‘patient perception of the disease’’ that appears to drive behavior.
Patient reports of medication behaviors reflect the combined
decisions of themselves and their physicians. A woman can only be
on treatment if her doctor prescribes a medication and she elects to
take it. Conversely, she may decide to discontinue AOM herself or
Figure 3. Multivariable HRs predicting switching AOM (c=0.70). AOM, anti-osteoporosis medication; BMI, body mass index; CI, confidence
interval; HR, hazard ratio. aAsthma, chronic bronchitis or emphysema, osteoarthritis or degenerative joint disease, rheumatoid arthritis, stroke,
ulcerative colitis or Crohn’s, celiac disease, Parkinson’s disease, multiple sclerosis, cancer, type 1 diabetes, hypertension, heart disease, high
cholesterol concentration.
doi:10.1371/journal.pone.0082840.g003
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with her doctor’s advice. Therefore, having only subject reports,
we were unable to identify the sources of any decisions.
Each survey represents a cross-sectional assessment, hence,
determining antecedent–consequent relationships is not possible.
For example, heightened concern about osteoporosis may either
precede and precipitate initiation of treatment or may be a
consequence of the decision to begin AOM. However, in most
cases, a woman’s attributes, attitudes, and actions are clustered in
a way that such distinctions are not critical to understanding
behavior.
Our high-risk designation for women was based on estimates
derived from the FRAX tool which, although based on well-
established risk factors for fracture, was not published until 2008.
As our baseline collection of data took place in 2007, clinicians
would not have had FRAX algorithms available for assessing their
patients. However, clinical risk factors associated with fracture
were recognized and acknowledged well before the publication
and dissemination of FRAX [38].
The strengths of this study include the large sample size and the
uniform method of collecting data across study sites. Data were
gathered from patients of primary care physicians and there were
few exclusion criteria. Physicians did not select specific patients for
this study; they merely provided lists of active patients so the
overall group to whom the questionnaires were sent initially should
be representative of the practices.
Conclusions
Many women who are at high risk of fracture are not taking
medication that could reduce their risk. Those who do initiate
treatment are more likely to self-report a diagnosis of osteoporosis
or osteopenia, and appear to be motivated primarily by concern
about osteoporosis and risk of fracture. Women who stop their
medication are more likely to believe they do not have
osteoporosis.
Supporting Information
Table S1 Univariate HRs for stopping, switching, or
starting AOM among high-risk women.
(DOCX)
Figure 4. Multivariable HRs predicting starting AOM (c=0.77). AOM, anti-osteoporosis medication; CI, confidence interval; HR, hazard ratio.
doi:10.1371/journal.pone.0082840.g004
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